

<b>*Evolent</b>	
<b>Clinical Guideline:</b> <b>NEUTRON BEAM THERAPY (NBT)</b>	<b>Original Date: November 2013</b>
<b>CPT Codes: 77422, 77423</b>	<b>Last Revised Date: May 2023</b>
<b>Guideline Number: Evolent_CG_229</b>	<b>Implementation Date: January 2024</b>

### GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

### INDICATIONS FOR NEUTRON BEAM THERAPY

- Neutron beam treatment is indicated for salivary gland cancers that are inoperable, recurrent, or are resected with gross residual disease or positive margins.<sup>1</sup>
- Other uses of Neutron Beam Therapy are considered investigational and therefore are not approved because its effectiveness for these indications has not been established.

### BACKGROUND

Neutron Beam Therapy (NBT) is a type of radiation treatment that uses a particle accelerator so is not readily available in most of the country. Protons from the accelerator create a neutron beam that attacks cancer cells with more power than conventional radiation therapy. Neutrons are much heavier than photons, thus appear to be more effective in destroying very dense tumors. With neutron beam treatment, the risk of side effects on healthy tissue near the cancer site is greater, requiring equipment to precisely focus the beam and block exposure to any surrounding tissue. Currently, both the availability and the criteria for use are very limited.

#### Overview:

NBT has been employed mainly for the treatment of the salivary gland cancers. It has also been used to treat other malignancies such as soft tissue sarcoma, lung, pancreatic, colon, kidney, and prostate cancers. Nevertheless, NBT has not gained wide acceptance because of the clinical difficulty in generating neutron particles and limited publications.

The safety and efficacy of neutron beam radiation therapy has not been established in the published medical literature. Complication rates were increased for NBT compared to other forms of external beam radiation therapy, and questions remain with regard to patient selection criteria, technical parameters, and comparative efficacy to other treatment modalities.

## REFERENCES

1. American Cancer Society. Radiation Therapy for Salivary Gland Cancer. Updated March 18, 2022. Accessed December 2, 2022. <https://www.cancer.org/cancer/salivary-gland-cancer/treating/radiation-therapy.html>

**POLICY HISTORY**

<b>Date</b>	<b>Summary</b>
May 2023	Deleted Additional Resources
January 2022	No changes

## Reviewed / Approved by Clinical Guideline Committee

**Disclaimer:** *Evolut Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Evolut uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. **Members should contact their Plan customer service representative for specific coverage information.***